Best Altcoin to Buy During the Crypto Crash - 20 November

Crypto bloodbath creates prime buying opportunity for savvy investors

The Silver Lining in Red Candles

While paper hands panic-sell, seasoned traders recognize market corrections as discount shopping days. The 20 November crypto crash wiped billions from market caps—and smart money's already circling undervalued altcoins.

Buy When There's Fear in the Streets

Market psychology dictates that maximum fear creates maximum opportunity. Retail investors fleeing the space creates the perfect entry points for assets with strong fundamentals and real utility. The current selloff represents one of those rare moments where sentiment overshadows substance.

Altcoin Selection Strategy

Focus on projects with proven technology, active development, and sustainable tokenomics. Avoid meme coins and projects without clear roadmaps. The crash separates serious blockchain innovations from speculative gambles.

Remember what they say on Wall Street—the time to buy is when there's blood in the streets, even if it's your own. In crypto, that wisdom gets amplified by 10x.

Key Takeaways

• Abbott Laboratories has agreed to acquire Exact Sciences Corp. in a deal worth $21 billion, paying shareholders $105 per share.
• Exact Sciences makes a variety of cancer screening tests, including Cologuard, and expects to generate about $3 billion in revenue this year.
• Many pharmaceutical companies are spending billions to develop screenings and treatments for a variety of cancers, as millions of people are diagnosed with cancer every year.

Shares of cancer screening test Maker Exact Sciences Corp. (EXAS) surged Thursday after Abbott Laboratories (ABT) announced a deal to acquire the company for about $21 billion.

Abbott said Thursday it will pay out $105 per share to Exact Sciences' shareholders, and that it expects the deal to close in the second quarter of next year.

Exact Sciences makes a range of cancer screening products, including Cologuard and other tests. Abbott said in its press release that the "cancer screening and precision oncology diagnostics" market in the U.S. is worth about $60 billion total.

In its most recent quarterly report earlier this month, Exact Sciences said it made $851 million in revenue in the third quarter and lifted its full-year revenue forecast to a range of $3.22 billion to $3.235 billion.

Why This Matters to Investors

Some of the largest pharmaceutical companies in the world have spent billions to expand their own efforts or license and acquire other companies that are developing treatments, vaccines and screenings for various types of cancer. The target companies with innovative and promising products can command huge prices, which pays off significantly for shareholders.

Ahead of the announcement, Oppenheimer analysts wrote that the reported potential deal made sense for Abbott on a fundamentals level, but said that how the deal WOULD be financed likely matters more for Abbott in the long run, as paying a high valuation could make the deal less attractive to investors.

Globally, studies have estimated the cancer screening market was worth more than $100 billion last year, and is projected to grow 6% to 8% annually over the next several years as population continues to expand, and the number of people diagnosed with cancer also increases. In the press release, Abbott said about 2 million people in the U.S. and 20 million people globally are diagnosed with cancer every year.

Exact Sciences' shares ROSE 17% to just under $101, closing at their highest level in four years. The stock has gained roughly 80% since the start of 2025.

Abbott shares finished the day down nearly 2%. The stock is up 10% this year, lagging the performance of the S&P 500.

Related Education